238 related articles for article (PubMed ID: 18213632)
1. The metabolites citrate, myo-inositol, and spermine are potential age-independent markers of prostate cancer in human expressed prostatic secretions.
Serkova NJ; Gamito EJ; Jones RH; O'Donnell C; Brown JL; Green S; Sullivan H; Hedlund T; Crawford ED
Prostate; 2008 May; 68(6):620-8. PubMed ID: 18213632
[TBL] [Abstract][Full Text] [Related]
2. Citrate concentrations in human seminal fluid and expressed prostatic fluid determined via 1H nuclear magnetic resonance spectroscopy outperform prostate specific antigen in prostate cancer detection.
Kline EE; Treat EG; Averna TA; Davis MS; Smith AY; Sillerud LO
J Urol; 2006 Nov; 176(5):2274-9. PubMed ID: 17070311
[TBL] [Abstract][Full Text] [Related]
3. Proton MRS of human prostatic fluid: correlations between citrate, spermine, and myo-inositol levels and changes with disease.
Lynch MJ; Nicholson JK
Prostate; 1997 Mar; 30(4):248-55. PubMed ID: 9111602
[TBL] [Abstract][Full Text] [Related]
4. Citrate in expressed prostatic secretions has the feasibility to be used as a useful indicator for the diagnosis of category IIIB prostatitis.
Chen J; Xu Z; Zhao H; Jiang X
Urol Int; 2007; 78(3):230-4. PubMed ID: 17406132
[TBL] [Abstract][Full Text] [Related]
5. A decrease in 1H nuclear magnetic resonance spectroscopically determined citrate in human seminal fluid accompanies the development of prostate adenocarcinoma.
Averna TA; Kline EE; Smith AY; Sillerud LO
J Urol; 2005 Feb; 173(2):433-8. PubMed ID: 15643195
[TBL] [Abstract][Full Text] [Related]
6. Prostate cancer molecular markers GSTP1 and hTERT in expressed prostatic secretions as predictors of biopsy results.
Crocitto LE; Korns D; Kretzner L; Shevchuk T; Blair SL; Wilson TG; Ramin SA; Kawachi MH; Smith SS
Urology; 2004 Oct; 64(4):821-5. PubMed ID: 15491741
[TBL] [Abstract][Full Text] [Related]
7. Quantitative and qualitative characterization of 1H NMR spectra of colon tumors, normal mucosa and their perchloric acid extracts: decreased levels of myo-inositol in tumours can be detected in intact biopsies.
Moreno A; Arús C
NMR Biomed; 1996 Feb; 9(1):33-45. PubMed ID: 8842031
[TBL] [Abstract][Full Text] [Related]
8. A [-2]proPSA-based artificial neural network significantly improves differentiation between prostate cancer and benign prostatic diseases.
Stephan C; Kahrs AM; Cammann H; Lein M; Schrader M; Deger S; Miller K; Jung K
Prostate; 2009 Feb; 69(2):198-207. PubMed ID: 18942119
[TBL] [Abstract][Full Text] [Related]
9. Metabolite interactions in prostatic fluid mimics assessed by
Jupin M; van Heijster FHA; Heerschap A
MAGMA; 2022 Aug; 35(4):683-694. PubMed ID: 34919194
[TBL] [Abstract][Full Text] [Related]
10. Correlation of endorectal 2D JPRESS findings with pathological Gleason scores in prostate cancer patients.
Nagarajan R; Gomez AM; Raman SS; Margolis DJ; McClure T; Thomas MA
NMR Biomed; 2010 Apr; 23(3):257-61. PubMed ID: 19795373
[TBL] [Abstract][Full Text] [Related]
11. Percent free prostate-specific antigen (PSA) is an accurate predictor of prostate cancer risk in men with serum PSA 2.5 ng/mL and lower.
Walz J; Haese A; Scattoni V; Steuber T; Chun FK; Briganti A; Montorsi F; Graefen M; Huland H; Karakiewicz PI
Cancer; 2008 Nov; 113(10):2695-703. PubMed ID: 18853417
[TBL] [Abstract][Full Text] [Related]
12. Is quantitative histologic examination useful to predict nonorgan-confined prostate cancer when saturation biopsy is performed?
Pepe P; Fraggetta F; Galia A; Grasso G; Piccolo S; Aragona F
Urology; 2008 Dec; 72(6):1198-202. PubMed ID: 19041023
[TBL] [Abstract][Full Text] [Related]
13. Quantification of metabolites in breast cancer patients with different clinical prognosis using HR MAS MR spectroscopy.
Sitter B; Bathen TF; Singstad TE; Fjøsne HE; Lundgren S; Halgunset J; Gribbestad IS
NMR Biomed; 2010 May; 23(4):424-31. PubMed ID: 20101607
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of short-TE (1)H MRSI for quantification of metabolites in the prostate.
Basharat M; Jafar M; deSouza NM; Payne GS
NMR Biomed; 2014 Apr; 27(4):459-67. PubMed ID: 24519849
[TBL] [Abstract][Full Text] [Related]
15. Acute dextro-amphetamine administration does not alter brain myo-inositol levels in humans and animals: MRS investigations at 3 and 18.8 T.
McGrath BM; McKay R; Dave S; Seres P; Weljie AM; Slupsky CM; Hanstock CC; Greenshaw AJ; Silverstone PH
Neurosci Res; 2008 Aug; 61(4):351-9. PubMed ID: 18508145
[TBL] [Abstract][Full Text] [Related]
16. Multidimensional MR spectroscopic imaging of prostate cancer in vivo.
Thomas MA; Nagarajan R; Huda A; Margolis D; Sarma MK; Sheng K; Reiter RE; Raman SS
NMR Biomed; 2014 Jan; 27(1):53-66. PubMed ID: 23904127
[TBL] [Abstract][Full Text] [Related]
17. Can prostate-specific antigen and prostate-specific antigen velocity be used for prostate cancer screening in men older than 70 years?
Mouraviev V; Broadwater G; Sun L; Mayes JM; Moul JW; Polascik TJ
Urology; 2008 Jun; 71(6):1020-3. PubMed ID: 18267331
[TBL] [Abstract][Full Text] [Related]
18. Ultra high field NMR spectroscopic studies on human seminal fluid, seminal vesicle and prostatic secretions.
Lynch MJ; Masters J; Pryor JP; Lindon JC; Spraul M; Foxall PJ; Nicholson JK
J Pharm Biomed Anal; 1994 Jan; 12(1):5-19. PubMed ID: 8161606
[TBL] [Abstract][Full Text] [Related]
19. TE = 32 ms vs TE = 100 ms echo-time (1)H-magnetic resonance spectroscopy in prostate cancer: Tumor metabolite depiction and absolute concentrations in tumors and adjacent tissues.
Basharat M; Payne GS; Morgan VA; Parker C; Dearnaley D; deSouza NM
J Magn Reson Imaging; 2015 Oct; 42(4):1086-93. PubMed ID: 26258905
[TBL] [Abstract][Full Text] [Related]
20. Proton magnetic resonance spectroscopy (1H-MRS) reveals the presence of elevated myo-inositol in the occipital cortex of blind subjects.
Bernabeu A; Alfaro A; García M; Fernández E
Neuroimage; 2009 Oct; 47(4):1172-6. PubMed ID: 19426816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
